Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

3(42.9%)

Phase 3

2(28.6%)

Phase 1

1(14.3%)

Phase 4

1(14.3%)

7Total

Phase 2(3)

Phase 3(2)

Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05289947Phase 2Completed

MLC1501 Study Assessing Efficacy in Post STrOke Subjects With mOtor Deficits

Role: lead

NCT07191028Phase 3Not Yet Recruiting

Alzheimer's Disease THErapy With NEuroaid II

Role: lead

NCT02537899Phase 4Completed

Spinal Cord Injury - Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD

Role: lead

NCT06228638Unknown

CognivAiD Real-World Evidence Clinical Registry (CONNECT Registry)

Role: lead

NCT05046106Phase 2Not Yet Recruiting

MLC1501 Study Assessing Efficacy in STROke Recovery

Role: lead

NCT04861688Phase 3Completed

NeuroAiD II™ (MLC901) in Mild Traumatic Brain Injury

Role: lead

NCT02536079Unknown

NeuroAiD Safe Treatment Registry

Role: collaborator

NCT04233437Phase 1Completed

Drug-Drug Interaction Study of MLC1501 Using Cocktail of Drugs Acting as Sensitive Clinical Probes/Substrates of Cytochrome P450 Isoenzymes and Transporters in Healthy Subjects

Role: lead

NCT00721825Phase 2Completed

Study of NeuroAid In Enhancing Recovery After Stroke

Role: lead

All 9 trials loaded